Cantor Fitzgerald’s CERo Therapeutics Warrants CEROW Stock Holding History

Cantor Fitzgerald’s Portfolio CEROW Stock Details CEROW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-441,048	Closed	-$10.5K	–	561
2025 Q2	$10.5K	Hold	441,048	–	–	﹤0.01%	422
2025 Q1	$6.39K	Hold	441,048	–	–	﹤0.01%	294
2024 Q4	$4.1K	Hold	441,048	–	–	﹤0.01%	260
2024 Q3	$2.25K	Hold	441,048	–	–	﹤0.01%	206
2024 Q2	$8.87K	Hold	441,048	–	–	﹤0.01%	223
2024 Q1	$35.2K	Buy	441,048 +77,500	+21%	+$4.71K	0.01%	188
2023 Q4	$8.54K	Hold	363,548	–	–	﹤0.01%	208
2023 Q3	$26K	Hold	363,548	–	–	﹤0.01%	489
2023 Q2	$22.2K	Hold	363,548	–	–	﹤0.01%	514
2023 Q1	$14.6K	Hold	363,548	–	–	﹤0.01%	614
2022 Q4	$16K	Hold	363,548	–	–	﹤0.01%	648
2022 Q3	$29K	Hold	363,548	–	–	﹤0.01%	672
2022 Q2	$36K	Hold	363,548	–	–	﹤0.01%	726
2022 Q1	$79K	Sell	363,548 -11,452	-3%	-$4.25K	0.01%	306
2021 Q4	$158K	Buy	+375,000	New	+$173K	0.01%	287

Other funds holding CEROW

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

QGA

Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Cantor Fitzgerald's CEROW Position: Q3 2025 in Review

Cantor Fitzgerald sold out of CERo Therapeutics Warrants (CEROW) in Q3 2025, closing a stake of 441,048 shares — an estimated $10.5K sold.

Cantor Fitzgerald first reported a position in CEROW in Q4 2021 and held it in 15 quarters. The position peaked at $158K in Q4 2021. 22 funds tracked by Wall St. Rank hold CEROW as of Q3 2025.

Cantor Fitzgerald reported no remaining CERo Therapeutics Warrants position as of Q3 2025 after selling out during the quarter.
Cantor Fitzgerald sold 441,048 CERo Therapeutics Warrants shares in Q3 2025, an estimated $10.5K.
Cantor Fitzgerald first reported a position in CERo Therapeutics Warrants in Q4 2021 and held it in 15 quarters.
Cantor Fitzgerald's CERo Therapeutics Warrants position peaked at $158K in Q4 2021.
22 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q3 2025.

Based on Cantor Fitzgerald's 13F filing for Q3 2025, filed 14 Nov 2025.